nVent Electric plc Ordinary Shares NVT 深 滬
等待開盤 12-23 09:30:00 美东时间
102.79
+1.250
+1.23%
華盛通- 最 高103.44
- 今 開103.22
- 成交量 160.52万股
- 最 低 101.40
- 昨 收 101.54
- 總市值 165.49亿
- 52周最高 117.52
- 市盈率 靜 52.11
- 換手率 1.00%
- 52周最低 41.105
- 委 比 -81.82%
- 總股本 1.61亿
- 歷史最高 117.52
- 量 比 0.45
- 振 幅 2.01%
- 歷史最低 6.35
- 每 手 1
- 風險率 18.86%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AI Stocks Tumble, Nvidia Hits 3-Month Lows: What's Moving Markets Wednesday?
Investors rushed to dump tech and AI-linked stocks on Wednesday, fueling a broad sector selloff reminiscent of the red days in October and November, when traders fretted over the risk of an AI bubble.
12-18 01:30
nVent Electric Increases Quarterly Dividend From $0.20 To $0.21 Per Share
nVent Electric plc (NYSE:NVT) announced today that its Board of Directors declared a regular quarterly cash dividend of US$0.21 per ordinary share for the first quarter of 2026, which represents an increase of 5% over
12-16 07:30
Shares of electrical equipment companies are trading lower amid overall market weakness.
Shares of electrical equipment companies are trading lower amid overall market ...
12-13 04:54
美股大行评级 | 潜在涨幅218.88%！Kyverna Therapeutics获摩根士丹利升目标价至25美元，维持"超配"评级
今日重点评级关注：摩根士丹利：维持Kyverna Therapeutics"超配"评级，目标价从20美元升至25美元；Maxim Group：维持Capricor Therapeutics"买入"评级，目标价从25美元升至50美元
12-05 08:35
Barclays Maintains Overweight on nVent Electric, Raises Price Target to $140
Barclays analyst Julian Mitchell maintains nVent Electric (NYSE:NVT) with a Overweight and raises the price target from $130 to $140.
12-04 23:51
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
UBS Initiates Coverage On nVent Electric with Buy Rating, Announces Price Target of $128
UBS analyst Neal Burk initiates coverage on nVent Electric (NYSE:NVT) with a Buy rating and announces Price Target of $128.
11-20 23:16
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
11-04 10:31
电话会总结 ｜ nVent(NVT)2025财年Q3业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据nVent业绩会实录，以下是Q3 2025财务业绩回顾摘要： ## 1. 财务业绩 **营收表现：** - Q3 2025销售额达到10.54亿美元，同比增长35%，首次单季度销售额突破10亿美元 - 有机增长16%，收购贡献1.39亿美元（18个百分点） - 汇率影响约1个百分点的正面贡献 **盈利能力：** - 调整后每股收益0.91美元，同比增长44%，创历史新高 - 调整后营业收入2.13亿美元，同比增长27% - 销售回报率20.2% **现金流：** - 自由现金流2.53亿美元，同比增长77% - 现金转换率预期90%-95% -
11-03 12:23
nVent Electric Boosts Outlook After First 'Billion-Dollar Quarter'
nVent Electric (NVT) reported Q3 results that beat expectations with adjusted earnings of 91 cents per share, up 44% from last year.
10-31 22:10
